Rationale: Vascular endothelial (VE)-cadherin localized at adherens junctions (AJs) regulates endothelial barrier function. Because WNT (wingless) signaling-induced activation of the transcription factor Krü ppel-like factor (KLF)4 may have an important role in mediating the expression of VE-cadherin and AJ integrity, we studied the function of KLF4 in regulating VE-cadherin expression and the control of endothelial barrier function. Objective: The goal of this study was to determine the transcriptional role of KLF4 in regulating VE-cadherin expression and endothelial barrier function.
T he vascular endothelium controls the exchange of solutes, hormones, and leukocytes between the blood and tissues. The regulation of vascular endothelial permeability participates critically in an array of physiological and pathological processes, including developmental and tumor angiogenesis, as well as immunity and inflammation. [1] [2] [3] [4] Vascular endothelial (VE)-cadherin is a single-pass homophilic cell adhesion protein localized at adherens junctions (AJs) that regulates endothelial barrier function, leukocyte trafficking, and angiogenesis. [1] [2] [3] [4] However, the underlying transcriptional mechanisms regulating VE-cadherin expression in endothelial cells (ECs) remain to be fully understood.
The Krüppel-like factors (KLFs) comprise a family of transcription factors containing the conserved C2H2 zinc finger DNA-binding domain. 5 KLF4, a homolog of KLF1, is a downstream target of WNT (wingless). 6 -10 KLF4 has an acidic transcriptional activation domain at the N terminus, and the C terminus contains 81 conserved amino acid residues that form 3 C2H2 zinc fingers that serve as the DNA-binding domain. 5, 11, 12 The presence of proline (P), glutamic acid (E), serine (S), and threonine (T) (PEST)-like sequence located between the transcriptional activation and inhibitory domains 11, 12 suggests that KLF4 may also be a target of ubiquitin-proteosomal proteolysis. The highly homologous zinc finger regions of KLF1 and KLF4 interact with a "CACCC" DNA sequence element of promoters/ enhancers of target genes. 11, 12 Human and mouse KLF4 share 90% amino acid identity, and 103 amino acid residues of the C terminus are 100% conserved. 11, 12 The ability of KLF4 to regulate the terminal differentiation of goblet cells 13 and to suppress expression of cyclin D1 and ornithine decarboxylase (ODC) 14, 15 suggests its critical role in cell cycle arrest. In vascular smooth muscle cells, KLF4 induces the expression of p21, p27, p53, and retinoblastoma, thereby inhibiting synthetic phenotypes of these cells. 16, 17 Although KLFs are expressed in ECs, 18 -22 and they may have a role in inflammation, 23, 24 the specific role of KLF4 in regulating VEcadherin expression, and thereby endothelial barrier function, remains unclear.
Klf4-deficient mice displayed a defect in the acquisition of skin barrier function and a rapid loss of body fluid as neonates. 25 The ectopic expression of Klf4 enhanced barrier function in the epidermis. 26, 27 Recent studies have shown expression of KLF4 in ECs under physiological conditions, and elevated expression of KLF4 in cultured ECs induced the expression of several antiinflammatory and antithrombotic factors, notably endothelial nitric oxide synthase and thrombomodulin (TM). In contrast, depletion of KLF4 enhanced the expression of tumor necrosis factor ␣ (TNF␣)-induced vascular cell adhesion molecule-1 (VCAM-1) and tissue factor (TF). [22] [23] [24] Thus, KLF4 appears to play a potential role in inflammation and monocyte differentiation. 28, 29 Conditional deletion of Klf4 in the surface ectoderm-derived tissues of the eye also resulted in corneal epithelial fragility, 30, 31 whereas elevated expression of Klf4 displayed an atheroprotective phenotype in ECs. [32] [33] [34] [35] [36] Deletion of the VE-cadherin gene in mice results in midgestational embryonic lethality caused by severe vascular developmental defects. 37 VE-cadherin gene expression is regulated by several transcription factors, including Etsbinding sites (EBS) and hypoxia response element (HRE), as well as nonspecific promoter elements. 38, 39 Our goal here was to address the role of KLF4 in mediating the expression of VE-cadherin and thereby determine whether KLF4 regulates endothelial barrier function.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Mouse anti-human KLF4 monoclonal antibody (H00009314-M01) was purchased from AbNOVA (Walnut, Calif). Goat anti-VEcadherin (sc-6458), rabbit anti-VE-cadherin (sc-28644), and mouse anti-GAPDH (sc-51906) antibodies; and control nonsilencing small interfering (si)RNA, Klf4-siRNA for mouse, VE-cadherin-siRNA, and KLF4-siRNA for human were purchased from Santa Cruz Biotechnology (Santa Cruz, Calif). VE-cadherin cDNA was purchased from Origene Technologies Inc (Rockville, Md). Anti-␤catenin (clone 14) monoclonal antibody was purchased from BD Biosciences (San Jose, Calif). Human, native, citrate-free thrombin was obtained from EMD Biosciences (La Jolla, Calif). Rabbit anti-mouse Klf2 was bought from Genway Biotech (San Diego, Calif). Anti-Klf6 was bought from Biolegend (San Diego, Calif).
Results

Expression of KLF4 in Endothelial Cells and Response to WNT3A Stimulation
We observed Klf4 expression in all tissues tested (Online Figure I ). In addition to the 55-kDa polypeptide, we observed fast mobility anti-Klf4 immunoreactive species in few tissues (Online Figure I ). Next, we analyzed expression of KLF4 and its function in early passage primary HUVECs to determine its role in EC junction homeostasis. HUVECs displaying the cobblestone morphology of confluent monolayers expressed abundant VE-cadherin protein and formed adherens junctions (AJs). To test the hypothesis that WNT3A regulates expression of VE-cadherin, we treated HUVECs with either lithium chloride (LiCl) or recombinant WNT3A. We used LiCl as a positive control because it has been shown to induce Wnt signaling by binding to and inactivating GSK-3␤, thereby stabilizing ␤-catenin. We observed uniform VE-cadherin zipper-like staining throughout the HUVEC monolayer (Figure 1A through 1F). Interestingly, we also observed increased VE-cadherin staining in HUVECs treated with LiCl and WNT3A ( Figure 1C through 1F). For additional images, see Online Figure II . Next, cell extracts prepared from these cells were analyzed by antibodies against VE-cadherin, ␤-catenin, and KLF4. Control HUVECs showed typical basal expression of VE-cadherin, ␤-catenin, and KLF4 proteins, whereas addition of LiCl and WNT3A increased the expression of these proteins without changing GAPDH expression ( Figure  1G greater phenotypic response in HUVECs than the canonical Wnt ligand WNT3A. However, HUVECs expressed higher levels of VE-cadherin, KLF4, and ␤-catenin in response to WNT3A addition. We observed at least 2 anti-VE-cadherin immunoreactive polypeptides in these cells ( Figure 1G ). WNT3A stimulation decreased the level of faster mobility species and conversely increased the level of the slower mobility species (Figure 1G , last lane). Using RT-PCR, we also detected increased expression of ␤-catenin and KLF4 transcripts in HUVECs stimulated with LiCl or WNT3A (Online Figure 
KLF4 Depletion Disrupts AJs in Microvascular Endothelial Cells and Increases Transendothelial Permeability
EC monolayer junction barrier integrity was monitored in real time by transendothelial electrical resistance (TER) measurements. Because thrombin induces EC contraction and endothelial barrier disruption, it was used as a positive control for endothelial barrier disruption in the TER assay. To test the hypothesis that KLF4 depletion impairs endothelial barrier function, TER was monitored in human lung microvascular endothelial cells (HLMVECs) treated with control siRNA or KLF4-siRNA (time line of experiments is shown in Figure  2A ). We observed decreased TER in control HLMVECs and HLMVECs treated with control siRNA following thrombin challenge (arrow), indicating thrombin-induced opening of AJs ( Figure 2B ). TER returned to baseline within 3 hours of thrombin (50 nmol/L) challenge ( Figure 2B ). KLF4-depleted HLMVECs, however, showed lower baseline TER ( Figure  2B ), indicating higher basal AJ permeability compared with control HLMVECs or control siRNA-treated HLMVECs (PϽ0.05, nϭ7). Addition of thrombin to KLF4-depleted HLMVECs showed a further drop in TER ( Figure 2B ), indicating greater loss of AJ barrier integrity. KLF4-depleted monolayers also did not recover to baseline values following thrombin in contrast to control cells similarly challenged with thrombin ( Figure 2B ). Thus, KLF4 depletion in ECs showed loss of AJ integrity and enhanced endothelial barrier dysfunction in response to thrombin. Next, to address the role of KLF4 in transendothelial permeability to albumin, we used Transwell membrane filters to grow confluent endothelial monolayers ( Figure 2C through 2E). The time line of these experiments is shown in Figure  2C . Control HLMVECs and control siRNA showed basal permeability, whereas fluorescein isothiocyanate (FITC)albumin transendothelial permeability increased after thrombin addition (50 nmol/L) or following KLF4 depletion (Figure 2D ). FITC-albumin permeability was significantly higher in thrombin treated HLMVEC compared with KLF4 knockdown. Reexpression of VE-cadherin cDNA in KLF4-depleted HLMVECs restored albumin permeability ( Figure 2E ); however, the restoration was incomplete, suggesting that VEcadherin may not be the only target of KLF4. The efficiency of KLF4 knockdown and VE-cadherin reexpression in HLM-VECs was determined by Western blotting (Figure 2E ). 
KLF4 Binds to and Activates the VE-Cadherin Promoter
Because ECs constitutively express KLF4, KLF4 expression increases in response to WNT3A stimulation, as shown above, and KLF4 regulates endothelial junctional permeability, we determined the role of KLF4 in activating the VE-cadherin promoter. Analysis of human VE-cadherin promoter Ϫ1260 to ϩ1 relative to transcription start site (TSS) revealed 6 putative KLF4-binding sites (CACCC) in the human VE-cadherin promoter (VE-cadherin promoter is shown in Figure 3A ). The first 2 binding sites (CACCC) are located close to each other at Ϫ1254 to Ϫ1245 positions, whereas 4 binding sites are located at Ϫ696, Ϫ649, Ϫ565, and Ϫ413 upstream of TSS.
To test the hypothesis that KLF4 binds to the VE-cadherin promoter, primers were designed to bind sequences flanking the 6 putative KLF4-binding sites and amplify a 900-bp product from the chromatin in the chromatin immunoprecipitation (ChIP) assay ( Figure 3B ). ECs were either left untreated or treated with WNT3A for 3 days. Chromatin was obtained, and immunoprecipitations were performed using antibodies specific to KLF4 or GLUT-1 (control). We observed minimal basal binding of KLF4 to VE-cadherin promoter in control, untreated HLMVECs but binding increased in response to WNT3A stimulation ( Figure 3C ). There was no basal binding in HUVECs, but as with HLMVECs, increased KLF4 binding to the VE-cadherin promoter sequence in response to WNT3A stimulation was seen in these cells. The immunoprecipitation was specific for KLF4 because there was no detection of the VE-cadherin promoter when anti-GLUT-1 antibody was used for immunoprecipitation.
Next, we performed electrophoretic mobility-shift assays (EMSA) to determine interactions between KLF4 and the VE-cadherin promoter. We designed and synthesized 4 biotin-labeled oligonucleotide probes flanking both sites at Ϫ1254 and Ϫ1245 (probe 1, P1), Ϫ696 (probe 2, P2), Ϫ649 (probe 3, P3), and Ϫ565 (probe 4, P4) nucleotides ( Figure  3D ). Nuclear extracts were prepared from ECs stimulated with WNT3A. As shown in representative EMSA assay, we observed an interaction of KLF4 with the VE-cadherin DNA sequence element flanking nucleotide sites at Ϫ1254 and Ϫ1245 (Figure 3E, third lane) . In contrast, incubation with unlabeled oligos displaced the specific binding of KLF4 to the biotin-labeled VE-cadherin promoter DNA sequence ( Figure 3E , far right). We also observed interactions of KLF4 with P2, P3, and P4 biotinylated oligonucleotides (data not shown). Thus, WNT3A induced the expression of KLF4 and KLF4 binds to the VE-cadherin promoter DNA sequence at one or more sites upstream of TSS.
To determine whether WNT3A-induced activation of KLF4 is required for the VE-cadherin promoter activity, we also used the VE-cadherin promoter luciferase reporter constructs and performed transfection experiments (Figure 4 ). Wild-type (construct a) and deletion (b through e) constructs are shown in Figure 4A . The potential KLF4-binding sites are shown in Figure 4A (construct a) . The wild-type VE-cadherin reporter construct (construct a) contains 6 putative KLF4- binding sites, and deletion constructs b through e contain 4, 3, 2, and 1 site, respectively. ECs were cotransfected with a tracer amount of ␤-galactosidase together with wild-type (construct a) or with deletion constructs (b through e). The timeline of experiments is shown in Figure 4B . We observed basal luciferase activity in HLMVECs transfected with ␤-galactosidase alone ( Figure 4C ). However, HLMVECs cotransfected with wild-type (construct a) and deletion (b and c) constructs showed 2-, 1.5-, and 1.0-fold increase in luciferase activity ( Figure 4C ). Importantly, compared with untreated cells, WNT3A induced greater increases in luciferase activity in HLMVECs cotransfected with construct a (5-fold), construct b (2.5-fold), and construct c (2.0-fold). In contrast, there was no induction in HLMVECs transfected with deletion mutant constructs d and e ( Figure 4C ). Regardless of WNT3A treatment, there was no detectable luciferase activity in KLF4 knockdown HLMVECs cotransfected with wild-type construct a (Online Figure IV) . The efficiency of transfecting HLMVECs with or without WNT3A treatment was assessed subsequently by X-gal staining ( Figure 4D and 4E ).
Klf4 Depletion Augments Lipopolysaccharide-Induced Lung Polymorphonuclear Neutrophil Sequestration and Vascular Permeability
To determine whether depletion of mouse Klf4 decreases endothelial barrier function in vivo, we used lipopolysaccharide (LPS) (7.5 mg/kg body weight) to increase lung vascular permeability ( Figure 5 ). We monitored polymorphonuclear neutrophil (PMN) sequestration and extravascular water content in lungs because increased lung vascular permeability is coupled to increases in these parameters. Myeloperoxidase (MPO) activity (used to monitor PMN sequestration) increased steadily at 1, 3, and 6 hours after LPS ( Figure 5B ). At 1, 3, and 6 hours, LPS increased MPO activities to 4-, 6-, and 6-fold, respectively, in control and control siRNA-treated groups. Klf4-siRNAϩLPS resulted in significantly greater lung tissue MPO activities (5-, 7-, and 8-fold/mg lung tissue). The extent of Klf4 knockdown and downregulation of VEcadherin expression is shown in Figure 5C . There was no change in cyclin-D1 or Gapdh protein levels, whereas siRNA-mediated knockdown of Klf4 decreased VE-cadherin expression ( Figure 5C ). Control untreated mice exhibited normal lung architecture (Online Figure V, A and B) in contrast to LPS-challenged mice (Online Figure V , C through H). Importantly, Klf4-depleted group showed severe alveolar wall thickening, alveolar hemorrhage, and marked PMN sequestration (Online Figure V, H) . Lung tissue was also collected from these mice to measure extravascular water content (Online Figure V, I) . Untreated control mice and mice receiving control siRNA showed no edema and had wet/dry weight ratios of 4.6Ϯ1.6 and 4.3Ϯ1.8, respectively (nϭ24, *PϽ0.01). In contrast, control mice (treated with control siRNA construct or untreated) challenged with LPS showed increases in mean wet/dry weight ratio of 6.0Ϯ1.4 and 7.2Ϯ1.4, respectively (nϭ24, **PϽ0.05). The mean lung wet/dry weight ratio, however, was markedly increased in Klf4-depleted mice challenged with LPS (9.1Ϯ1.6). Thus, Klf4 depletion significantly augmented both lung PMN sequestration and water content in response to LPS, which was coupled to reduction in VE-cadherin expression and endothelial barrier integrity.
Although Klf2 and Klf6 are also expressed in mouse lung microvascular endothelial cells (Online Figure VI) , we observed that Klf2 and Klf6 did not compensate for the reduction in Klf4 expression (Online Figure VI) . Furthermore, comparison of accumulation of [ 131 I]albumin in lung parenchyma (used as a measure of vascular permeability) following Klf4 or VE-cadherin knockdown showed that reduction in expression of either Klf4 or VE-cadherin induced vascular leakage (Online Figure VII) .
Discussion
ECs respond to Wnt stimulation based on their ability to express and release multiple Wnt ligands, cell surface expression of Wnt receptors, and secretion of modulators of Wnt signaling pathway. 9 Activation of the canonical Wnt signaling pathway promotes the stabilization of a fraction of ␤-catenin. 6 -10 Stabilized ␤-catenin thereby functions to transduce Wnt signals and acts as a coactivator for the transcription factor T-cell factor/lymphocyte enhancer-binding factor (TCF/LEF-1). 6 -10 Transcription factor KLF4 has been identified as a key target of the Wnt signaling pathway. 6 -8 Here, we determined the possible role of the KLF4 in regulating VE-cadherin expression and, thus, the role of KLF4 as a crucial determinant of endothelial barrier function.
KLF4 is known to promote differentiation of vascular cells and induce cell cycle arrest of synthetic smooth muscle cells. 29, 32, 33, 35, 36 However, its role in regulating VE-cadherin expression and endothelial barrier function has not been addressed. Previous studies have described the obligatory function of VE-cadherin in the formation of AJs and regulation of endothelial permeability. [2] [3] [4] Because Klf4 Ϫ/Ϫ mice display impaired barrier function during development, 25 we posited that a functionally important link exists between KLF4 and VE-cadherin expression that thereby regulates endothelial barrier function.
We demonstrated, first, that Klf4 expression in all tissues tested, including ECs in their basal state 18, 20, 24 ; moreover, KLF4 was markedly upregulated in WNT3A-treated ECs. We also observed the fast mobility anti-KLF4 immunoreactive species. Because KLF4 has 2 PEST-like sequences, the fast mobility immunoreactive anti-KLF4 could represent the proteasome-mediated proteolytic product. However, the fast mobility protein may also be attributable to nonspecific immunoreactivity or presence of a minor antibody contaminant. We confirmed the expression of Klf4 by RT-PCR in lungs and heart (data not shown) and ECs. Although KLF4 expression is typically seen in pluripotent and embryonic stem cells, our data as well as previous findings, 18, 20, 24 clearly identified its presence in adult tissue and differentiated cells.
Thus, it appears that the transcriptional activity of KLF4 is involved in homeostasis of fully differentiated cells.
The observation that KLF4 was constitutively expressed in ECs and its expression could be induced by WNT prompted us to address the relationship between KLF4 and VEcadherin expression. Hence, we determined KLF4-mediated transcriptional regulation of VE-cadherin. Both human and mouse VE-cadherin promoters contain binding sites for transcription factors ETS1, HRE, and zinc finger domaincontaining factors such as KLF4. 38, 39 Whereas WNT is known to induce ␤-catenin and KLF4 expression in tumor cells, 6 -8 here, we observed the upregulation of ␤-catenin and KLF4 in normal ECs. We also demonstrated, by immunostaining and Western blotting, increased expression of VEcadherin in ECs stimulated with LiCl, a direct activator of Wnt signaling. To establish further the relationship between KLF4 and VE-cadherin promoter, we focused on the Ϫ1.3-kb promoter elements containing at least 6 CACCC sites, which are the putative KLF4-binding elements. 11, 12 Results from ChIP and EMSA experiments showed that KLF4 binds at least 4 of the CACCC sites in the VE-cadherin promoter. Results using the luciferase assay also demonstrated the essential role of KLF4 in activating the VE-cadherin promoter and the requirement of Wnt signaling in this response. It is important to note, however, that the VE-cadherin promoter is responsive to multiple stimuli including hypoxia and bacterial toxins 38, 39 ; thus, it is likely that the VE-cadherin promoter is not only under the sole transcriptional control of KLF4. Our experiments do not rule out the possibility that transcription factors (such as SP1, ETS, or HRE) can also cooperate with KLF4 to regulate expression of VE-cadherin.
Studies have shown that increased VE-cadherin expression typically stabilizes AJs and promotes endothelial barrier function. 1,2 Hence, we used the TER assay to measure changes in AJ integrity. In confluent endothelial monolayers, KLF4 knockdown decreased basal TER, indicating a key role of KLF4 in controlling endothelial barrier function. Also, depleting KLF4 resulted in AJ instability, as evidenced by a further decrease in TER in response to thrombin challenge of these cells and failure of the barrier function to fully recover. KLF4 knockdown also increased transendothelial albumin permeability of FITC-albumin, consistent with decreased TER values and opening of AJs secondary to the lowered VE-cadherin expression seen in these cells. This was also seen in lung vascular endothelium of mice in which Klf4 depletion disrupted the vascular barrier, as evidenced by greater pulmonary edema formation in response to LPS challenge, as well as greater lung PMN sequestration. Therefore, our data demonstrate that KLF4 depletion results in decreased TER and increased transendothelial albumin permeability by preventing the expression of VE-cadherin. Because KLFs regulate the expression of inflammatory mediators, 28 we cannot rule out the possibility that the observed effects of KLF4 depletion in increasing endothelial permeability and PMN sequestration were secondary to increased production of such permeability-increasing mediators. An important caveat in these studies is that KLF4 does not solely regulate VE-cadherin expression and integrity of endothelial junctions. Other factors, such as tyrosine phosphorylation of VE-cadherin and VE-cadherin cleavage by ADAM10 (A disintegrin and metallopeptidase 10), are also known to influence junctional integrity by interfering with VE-cadherin function. 40, 41 In summary, we have shown for the first time that KLF4 binds to the VE-cadherin promoter in mature ECs and induces VE-cadherin transcription and is required for the maintenance of normal endothelial barrier function. It is possible in this context that KLF4 makes AJ barrier more resistant to inflammatory stimuli and serves to prevent vascular leakage. This function of KLF4 may be important in development of blood vessels with normal AJs during angiogenesis, and it is possible, therefore, that agent capable of activating KLF4 function could promote of normalization of blood vessels in ischemic cardiac diseases.
